Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
47°
Rain
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Fsd Pharma Inc Cl B
(CSE:
HUGE
)
0.5100
-0.0200 (-3.77%)
Streaming Delayed Price
Updated: 12:39 PM EDT, May 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Fsd Pharma Inc Cl B
< Previous
1
2
3
4
5
6
7
Next >
FSD Pharma Issues Corporate Updates
April 06, 2022
From
FSD Pharma Inc.
Via
Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Announces Filing of Year-End 2021 Results
March 31, 2022
Via
Investor Brand Network
FSD Pharma Announces Filing of Year-End 2021 Results
March 31, 2022
From
FSD Pharma Inc.
Via
Business Wire
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Spotlighted in Recent EIO Report from Crystal Research Associates
March 15, 2022
Via
Investor Brand Network
FSD Pharma Announces Executive Informational Overview Report Produced by Crystal Research Associates LLC
March 15, 2022
From
FSD Pharma Inc.
Via
Business Wire
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement for Sale of Cobourg Facility for CAD$16.5M
February 25, 2022
Via
Investor Brand Network
Topics
Cannabis
Exposures
Cannabis
FSD Pharma Announces Agreement for Sale of Cobourg Facility for CAD$16,500,000
February 25, 2022
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) Unveils Newly Designed Website
January 20, 2022
Via
Investor Brand Network
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Unveils Newly Designed Corporate Website
January 20, 2022
Via
Investor Brand Network
FSD Pharma Announces Launch of New Corporate Website
January 20, 2022
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) Board Member Named to the Order of Canada
January 18, 2022
Via
Investor Brand Network
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board Member Named to the Order of Canada
January 18, 2022
Via
Investor Brand Network
FSD Pharma Congratulates Dr. Eleanor Fish on Being Named to the Order of Canada
January 18, 2022
From
FSD Pharma Inc.
Via
Business Wire
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Participation in Upcoming H.C. Wainwright Bioconnect Conference
January 04, 2022
Via
Investor Brand Network
FSD Pharma to Present at the H.C. Wainwright Bioconnect Conference on January 10-13th
January 04, 2022
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board Approves Share Repurchase Program
December 30, 2021
Via
Investor Brand Network
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board Approves Share Repurchase Program
December 30, 2021
Via
Investor Brand Network
FSD Pharma Announces Share Repurchase Program
December 30, 2021
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) Shares Preclinical Data Demonstrating Positive Effects of Lucid-MS in Treating MS
December 23, 2021
Via
Investor Brand Network
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) Announces Establishment of Advisory Board, Strategic Appointments
December 23, 2021
Via
Investor Brand Network
FSD Pharma Establishes New Regulatory Advisory Board with the Appointment of Joga Gobburu, Ph.D., and Mary Melnyk, Ph.D., as Members
December 09, 2021
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma to Present at the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th
December 03, 2021
From
FSD Pharma Inc.
Via
Business Wire
The Power Play by the Market Herald Releases New Interviews With Lumiera, Fsd Pharma, HydroGraph, and Adastra Holdings
December 02, 2021
VANCOUVER, BC / ACCESSWIRE / December 2, 2021 / The Power Play by The Market Herald has announced the release of new interviews with Lumiera, FSD Pharma, HydroGraph, and Adastra Holdings discussing...
From
The Market Herald
Via
AccessWire
FSD Pharma Unveils Videos Demonstrating Positive Effects of Lucid-MS in Treating Multiple Sclerosis in Pre-Clinical Models (Mouse Models)
December 02, 2021
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma Expands Research and Clinical Advisory Board with Appointment of World-Renowned Immunologist and Cytokine Expert Dr. Eleanor N. Fish
November 16, 2021
From
FSD Pharma Inc.
Via
Business Wire
Ketamine’s Potential As A Treatment For Depression Has Drawn Major Industry Attention
October 27, 2021
Palm Beach, FL –October 27, 2021 – FinancialNewsMedia.com News Commentary – Among the race to see what psychedelic drugs can do, ketamine is a step ahead of all other drugs, because it has already been...
Via
FinancialNewsMedia
Exposures
Product Safety
FSD Pharma Signs Agreement with Covar Pharmaceuticals to Support the Development of Lucid-PSYCH
October 19, 2021
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma Announces Engagement with Capital Markets Communications Providers and Market Maker
September 22, 2021
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma Announces Closing of Lucid Psycheceuticals Acquisition
September 21, 2021
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma Announces Definitive Agreement to Acquire Lucid Psycheceuticals
August 25, 2021
From
FSD Pharma Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.